GenMark Diagnostics Shows Rising Price Performance With Jump To 86 RS Rating

On Wednesday, GenMark Diagnostics (GNMK) received an upgrade to its Relative Strength (RS) Rating, from 76 to 86.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock’s price action over the last 52 weeks matches up against other publicly traded companies.

Over 100 years of market history shows that the best stocks tend to have an 80 or better RS Rating as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

GenMark Diagnostics is working on a cup without handle with a 20.98 buy point. See if it can break out in volume at least 40% above average. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


Earnings growth picked up last quarter from 0% to 75%. But sales fell from 118% to 104%. The company is expected to report its latest results on or around Mar. 2.

The company earns the No. 12 rank among its peers in the Medical-Systems/Equipment industry group. Inmode (INMD) and Idexx Laboratories (IDXX) are also among the group’s highest-rated stocks.


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button